RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+14.22%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$949M
AUM Growth
+$949M
(+4.1%)
Cap. Flow
-$29.1M
Cap. Flow
% of AUM
-3.06%
Top 10 Holdings %
Top 10 Hldgs %
31.29%
Holding
98
New
10
Increased
21
Reduced
41
Closed
15
Top Buys
| 1 |
Eli Lilly
LLY
|
$38M |
| 2 |
Zimmer Biomet
ZBH
|
$20.1M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$13.4M |
| 4 |
Intuitive Surgical
ISRG
|
$11.6M |
| 5 |
Procept Biorobotics
PRCT
|
$9.86M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$21.1M |
| 2 |
Tenet Healthcare
THC
|
$9.77M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$9.44M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$8.61M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$8.33M |
Sector Composition
| 1 | Healthcare | 99.42% |
| 2 | Industrials | 0.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $38M | 4% | +81,000 | New | +$38M |
|
|
2
BioMarin Pharmaceuticals
BMRN
$11.2B
| $32.9M | 3.47% | 380,000 +155,000 | +69% | +$13.4M |
|
3
Cigna
CI
$80.3B
| $32.3M | 3.4% | 114,985 +30,485 | +36% | +$8.55M |
|
4
Boston Scientific
BSX
$156B
| $31.4M | 3.31% | 580,000 -20,000 | -3% | -$1.08M |
|
5
McKesson
MCK
$85.4B
| $30.3M | 3.2% | 71,000 +9,000 | +15% | +$3.85M |
|
6
UnitedHealth
UNH
$281B
| $28.8M | 3.04% | 60,000 -16,000 | -21% | -$7.69M |
|
7
Abbott
ABT
$231B
| $27.1M | 2.86% | 249,000 +64,000 | +35% | +$6.98M |
|
8
Medtronic
MDT
$119B
| $25.7M | 2.71% | 292,000 +57,000 | +24% | +$5.02M |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $25.1M | 2.65% | 35,000 -500 | -1% | -$359K |
|
10
Becton Dickinson
BDX
$55.3B
| $25.1M | 2.64% | 95,000 -7,000 | -7% | -$1.85M |
|
11
Elevance Health
ELV
$71.8B
| $24.9M | 2.62% | 56,000 | – | – |
|
|
12
Tenet Healthcare
THC
$16.3B
| $23.6M | 2.49% | 290,000 -120,000 | -29% | -$9.77M |
|
13
Cencora
COR
$56.5B
| $22.9M | 2.41% | 119,000 -30,000 | -20% | -$5.77M |
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $22.3M | 2.36% | 63,500 -20,000 | -24% | -$7.04M |
|
15
Merck
MRK
$210B
| $21.9M | 2.31% | 190,000 -51,000 | -21% | -$5.88M |
|
16
Humana
HUM
$36.5B
| $20.6M | 2.17% | 46,000 +16,000 | +53% | +$7.15M |
|
17
Cooper Companies
COO
$13.4B
| $20.2M | 2.13% | 52,800 -15,200 | -22% | -$5.83M |
|
18
AbbVie
ABBV
$372B
| $20.2M | 2.13% | 150,000 -2,000 | -1% | -$269K |
|
|
19
Zimmer Biomet
ZBH
$21B
| $20.1M | 2.12% | +138,000 | New | +$20.1M |
|
20
HCA Healthcare
HCA
$94.5B
| $19.6M | 2.06% | 64,500 -19,500 | -23% | -$5.92M |
|
21
Biogen
BIIB
$19.4B
| $18.4M | 1.94% | 64,500 +17,000 | +36% | +$4.84M |
|
22
Gilead Sciences
GILD
$140B
| $18M | 1.9% | 234,000 -25,000 | -10% | -$1.93M |
|
23
Jazz Pharmaceuticals
JAZZ
$7.75B
| $18M | 1.89% | 145,000 -5,000 | -3% | -$620K |
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $17.3M | 1.82% | 190,000 +5,000 | +3% | +$456K |
|
25
CVS Health
CVS
$92.8B
| $17.1M | 1.81% | 248,000 +75,000 | +43% | +$5.18M |
|